|
|
Gene Symbol |
IGFBP1 |
|
Aliases |
AFBP, IBP1, IGF-BP25, PP12, hIGFBP-1 |
|
Entrez Gene ID |
|
|
Gene Name |
Insulin like growth factor binding protein 1 |
|
Chromosomal Location |
7p12.3 |
|
HGNC ID |
|
|
Summary |
This gene is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP N-terminal domain and a thyroglobulin type-I domain. The encoded protein, mainly expressed in the liver, circulates in the plasma and binds both insulin-like growth factors (IGFs) I and II, prolonging their half-lives and altering their interaction with cell surface receptors. This protein is important in cell migration and metabolism. Low levels of this protein may be associated with impaired glucose tolerance, vascular disease and hypertension in human patients. [provided by RefSeq, Aug 2017]
|
|
e!Ensembl
|
Protein Information |
|
Protein Name |
Insulin-like growth factor-binding protein 1, IBP-1, IGF-binding protein 1, IGFBP-1, alpha-pregnancy-associated endometrial globulin, amniotic fluid binding protein, binding protein-25, binding protein-26, binding protein-28, growth hormone independent-binding protein, placental protein 12 |
|
Function |
IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. Promotes cell migration. |
|
|
UniProt |
|
|
PDB |
|
|
|
|
Interactions |
| |
STRING |
MINT |
IntAct |
ENSP00000370473 |
P17936 |
P17936 |
|
| |
View interactions
|
|
| |
Associated Diseases
Disease group | Disease Name | References |
Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Russell-Silver syndrome |
|
Digestive System Diseases |
Biliary Cirrhosis |
|
Liver Fibrosis |
|
Liver Cirrhosis |
|
Endocrine System Diseases |
PCOS |
|
Neoplasms |
Colonic Neoplasms |
|
Nutritional and Metabolic Diseases |
Gluocose Intolerance |
|
Renal Disorder |
Kidney Failure |
|
Kidney Insufficiency |
|
Reproductive disorders |
Endometriosis |
|
Endometrioma |
|
Preeclampsia |
|
|
References |
|
|
|
PubMed ID |
Associated gene/s |
Associated condition |
Genetic Mutation |
Diagnostic Criteria |
Association with PCOS |
Ethnicity |
Conclusion |
|
SHBG |
|
|
|
Related
|
21 PCO, 18 obese women without menstrual disturbances and 9 Control |
obese women with PCO insulin influence ovarian androgen production and decreases the serum SHBG and IGFBP-1 which could contribute in the augmentation of the symptoms of PCO |
|
IGF-1 and IGF |
|
|
|
Related
|
10 PCOS, 12 hypopituitarism and 10 Control |
Women with PCOS have normal serum IGF-1 concentrations but IGFBP-1 levels, regulated by insulin, are low |
|
|
|
|
|
Related
|
|
Decreased serum level of IGFBP-1 is unlikely to be a mechanism for ovarian hyperandrogenism in PCOS |
|
Matrix metalloproteinases(MMPs) |
|
|
|
Related
|
42 PCOS and 30 Control |
MMPs may be implicated in the pathophysiology of PCOS either by regulating ovarian tissue remodeling or indirectly by facilitating IGF-I bioavailability through proteolysis of IGFBP-1 |
|
Glycodelin |
|
|
PCOS was diagnosed before pregnancy, and defined by oligomenorrhea (eight or fewer menstrual periods annually before pregnancy) and hyperandrogenism (elevated serum free testosterone concentration or hirsutism) |
Related
|
72 PCOS and 62 Control |
During the first trimester, serum glycodelin and IGFBP-1 concentrations are markedly decreased in PCOS, implicating endometrial epithelial and stromal dysfunction during periimplantation and early pregnancy as a possible mechanism for EPL in PCOS |
|
|
insulin sensitivity |
|
|
Related
|
15 PCOS and 10 Control |
Insulin sensitivity contributed to the difference in IGFBP-1 levels found in women with PCOS |
|
SHBG |
|
|
|
Direct
|
10 PCOS and 10 controls |
that there is no diurnal variation in SHBG concentrations and confirms the finding of a marked diurnal variation in the concentration of IGFBP-1 |
|
|
hyperinsulinemia and hyperandrogenemia |
|
|
Related
|
16 PCOS and 20 control |
insulin and body mass index are the major determinants of circulating IGFBP1 and that chronic hyperandrogenemia does not appear to further reduce serum IGFBP1 levels in obese or normal-weight women withPCOS |
|
SHBG and GH |
|
|
|
Related
|
8 PCOS |
specific secretion pattern of IGFBP-1 is not directly dependent on body fat mass but is regulated by insulin in both obese and non-obese patients. |
|
SHBG |
|
|
|
Related
|
6 PCOS |
|
|
|
|
|